Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature
Cureus · 17.02.2023
DOI: 10.7759/cureus.35094 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 17.02.2023. Verfasst von Wael T Mohamed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Missouri Kansas City, Kansas City, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Drug-induced liver injury (DILI) is one of the leading causes of death from acute liver failure (ALF) in the United States, accounting for approximately 13% of ALF cases in the United States. Selective androgen receptor modulators (SARMs) were first developed to increase muscle mass while avoiding the side effects of conventional androgenic steroids. Although not Food and Drug Administration (FDA) approved, they are widely available online and are consumed to enhance athletic performance. We report a 22-year-old, previously healthy male, who presented with a two-week history of worsening jaundice, nausea, fatigue, pruritus, dark urine, and light stools. He reported taking the SARM, RAD-140, for 16 weeks. Examination showed scleral icterus. The liver panel showed alkaline phosphatase (ALP) 5.3 µkat/L, alanine transaminase (ALT) 1.66 µkat/L, aspartate transaminase (AST) 1.18 µkat/L, direct bilirubin 294 µmol/L, total bilirubin 427.5 µmol/L, and international normalized ratio (INR) 0.9. Viral hepatitis and autoimmune panel were unremarkable. Alpha-1 antitrypsin and ceruloplasmin levels were within normal limits. Bile sludge was seen on ultrasound. Magnetic resonance cholangiopancreatography (MRCP) abdomen showed segmental narrowing of the intrahepatic ducts. Endoscopic retrograde cholangiopancreatography (ERCP) was unremarkable. Liver biopsy showed mixed portal hepatitis, cholestasis, and biliary reactive changes with ceroid-loaded macrophages; a picture consistent with DILI. The patient was treated supportively and discharged with scheduled hepatology follow-up. At the one-month follow-up, his total bilirubin had fallen from a peak of 530 mol/L to 188 mol/L. The diagnosis of DILI can be made based on the timing of exposure and the exclusion of other etiologies. Liver enzymes normalized three to 12 months after product discontinuation. We hope this report will remind primary care physicians of the potential hepatotoxic side effects of muscle-building compounds and encourage them to report suspected DILI to the FDA using the MedWatch system.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, University of Missouri Kansas City, Kansas City, USA.
- Pathology, University of Missouri Kansas City, Kansas City, USA.
- Gastroenterology and Hepatology, University of Missouri Kansas City, Kansas City, USA.
Zitieren
APA
Mohamed, W. T., Jahagirdar, V., Fatima, I., Ahmed, M. K., Jaber, F., Wang, K., Hassan, A., Ewing, E., Clarkston, W., & Likhitsup, A. (2023). Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. Cureus. https://doi.org/10.7759/cureus.35094
Vancouver
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Jaber F, Wang K, et al. Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. Cureus. 2023. doi:10.7759/cureus.35094
BibTeX
@article{Mohamed2023,
author = {Mohamed, Wael T and Jahagirdar, Vinay and Fatima, Ifrah and Ahmed, Mohamed K and Jaber, Fouad and Wang, Kevin and Hassan, Amira and Ewing, Eric and Clarkston, Wendell and Likhitsup, Alisa},
title = {Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature},
journal = {Cureus},
year = {2023},
doi = {10.7759/cureus.35094}
}
EUVIMED